

1. Record Nr.	UNINA9910799933503321
Titolo	Personalized nutrition as medical therapy for high risk diseases // edited by Nilanjana Maulik
Pubbl/distr/stampa	Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020] ©2020
ISBN	1-351-62183-1 1-315-11237-X
Descrizione fisica	1 online resource (365 pages)
Disciplina	615.854
Soggetti	Diet therapy Personalized medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Half Title -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Preface -- Acknowledgments -- Editor -- Contributors -- Chapter 1 Introduction -- 1.1 Introduction -- 1.2 What Does Personalization Mean -- 1.3 Where to Go from Here -- 1.4 Medicalization of Food -- 1.5 The Genome-Based Health Concept -- 1.6 Way Forward -- References -- Chapter 2 Personalized Nutrition: The New Era of Nutrition -- 2.1 Introduction -- 2.1.1 Defining Personalized Nutrition -- 2.1.2 Origins of Personalized Nutrition as a Formal Scientific Ideology -- 2.2 Theoretical Basis for Personalized Nutrition -- 2.3 Current Perspectives on Personalized Nutrition -- 2.3.1 Nutrient-Gene Interactions -- 2.3.1.1 Biomarkers -- 2.3.2 Altering Human Behavior -- 2.3.3 Age and Stages of Life -- 2.3.4 Gender -- 2.3.5 Environment: The Exposome -- 2.3.5.1 The Microbiome -- 2.3.6 Personalized Nutritional Strategies for Athletic Performance -- 2.4 Closing Remarks -- Abbreviations -- References -- Chapter 3 Personalized Nutrition in Cardiovascular Disease: From Concept to Realization -- 3.1 Epidemiology -- 3.2 Personalized Nutrition (PN) in CVD -- 3.3 PN1: A Healthy Reference Diet for CVD -- 3.4 Diet and CVD: Lessons from and Limitations of Observational Studies -- 3.5 Saturated Fat (SFA) Intake and CVD -- 3.6 Fat Quality and CVD -- 3.7 Protein

Intake and CVD Risk -- 3.8 Carbohydrate Intake and CVD Risk -- 3.8.1 Glycemic Index/Load (GI/GL) -- 3.8.2 Fiber -- 3.8.3 Glucose/Fructose -- 3.9 Dietary Cholesterol and Plant Sterols and Stanols and CVD Risk -- 3.9.1 Dietary Cholesterol -- 3.9.2 Plant Sterols and Stanols -- 3.9.3 Salt Intake and CVD Risk -- 3.10 PN1: Healthy Diet Recommendations for Patients with, or at Risk of, CVD -- 3.11 PN2: Tailoring Dietary Advice to Manage CVD Based on a Person's Phenotype. 3.12 PN3: Tailoring Nutritional Advice to Genetic Composition: From Concept to Realization -- 3.13 Genetics and CVD: Testing the Nature versus Nurture Hypothesis -- 3.14 GWAS and CVD -- 3.15 PN3: Proof of Concept from LIPGENE -- 3.16 PN3: The Challenge of Keeping Up with GWAS -- 3.17 Perspective on the Future of PN for CVD: Is Society Ready to Embrace Change? -- Abbreviations -- References -- Chapter 4 Nutraceuticals for Hypertension Control -- 4.1 Hypertension -- 4.2 Epidemiology -- 4.3 Hypertension Can Be Classified into Two Forms: Primary and Secondary -- 4.3.1 Primary Hypertension -- 4.3.1.1 Genetic Factors -- 4.3.1.2 Environmental Factors -- 4.3.1.3 Childhood Risk for Hypertension -- 4.3.2 Secondary Hypertension -- 4.3.3 Complications of Hypertension -- 4.3.4 Treatment of Hypertension -- 4.4 Minerals and Hypertension -- 4.4.1 Sodium -- 4.4.2 Potassium -- 4.4.3 Magnesium -- 4.4.4 Calcium -- 4.4.5 Zinc -- 4.4.6 Copper -- 4.4.7 Chromium -- 4.4.8 Selenium -- 4.4.9 Manganese -- 4.5 Macronutrients Affecting Hypertension -- 4.5.1 Protein -- 4.5.2 Fat and Fatty Acids -- 4.5.3 Carbohydrates -- 4.5.4 Fibers -- 4.6 Micronutrients and Hypertension -- 4.6.1 Vitamins -- 4.6.2 Coenzyme Q10 (Ubiquinone -- 4.7 Antihypertensive Herbs and Their Mechanism of Action -- 4.7.1 Antioxidant Defense -- 4.7.1.1 Flavonoids -- 4.7.1.2 *Vitis vinifera* (Grapevine)-Resveratrol -- 4.7.1.3 *Lycopersicon esculentum* (Tomato)-Lycopene -- 4.7.1.4 *Camellia sinensis* (Green Tea -- 4.7.2 Diuretics -- 4.7.2.1 *Taraxacum officinale* (Dandelion -- 4.7.2.2 *Petroselinum crispum* (Parsley -- 4.7.2.3 *Urtica dioica* (Stinging Nettle -- 4.7.3 ACE-Inhibitors -- 4.7.3.1 *Allium ursinum* (Ramsons -- 4.7.3.2 *Zingiber officinale* (Ginger -- 4.7.3.3 *Angelica sinensis* (Danggui -- 4.7.4 Vasorelaxant Activity: Direct Vasodilators -- 4.7.4.1 *Allium cepa* (Onion -- 4.7.4.2 *Allium sativum* (Garlic. 4.7.4.3 *Cinnamomum zeylanicum* (Cinnamon -- 4.7.5 Calcium Channel Blocker (CCB -- 4.7.5.1 *Piper nigrum* (Black Pepper -- 4.8 Interactions of Antihypertensive Herbs -- 4.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 5 Roles of Daily Diet and Beta-Adrenergic System in the Treatment of Obesity and Diabetes -- 5.1 Introduction -- 5.2 Role of Nutrition in the Development of Diabetes and Obesity -- 5.2.1 Nutrition in Diabetes -- 5.2.1.1 Micronutrients in Diabetes -- 5.2.1.2 Anthocyanins -- 5.2.1.3 Cocoa Flavanols -- 5.2.1.4 Resveratrol -- 5.2.1.5 Cinnamon -- 5.2.1.6 Milk and Dairy Products -- 5.2.1.7 Probiotics -- 5.2.2 Nutrition in Obesity -- 5.2.2.1 Probiotics -- 5.2.2.2 Quercetin -- 5.2.2.3 Resveratrol -- 5.2.2.4 Curcumin -- 5.2.2.5 Sulforaphane -- 5.3 Role of Nutrition in the Function of the Cardiovascular System -- 5.4 Cardiac Function in Diabetes and Obesity -- 5.4.1 Cardiac Dysfunction in Diabetes -- 5.4.2 Cardiac Function in Obesity -- 5.5 Diet and Beta-Adrenergic System Relation in Heart Function -- 5.6 Effect of β -ARs System on Heart Function in Diabetes and Obesity -- 5.7 β 3-ARs in Diabetes and Obesity -- 5.8 Regulation of β 3-ARs in Heart from Diabetic and Obese Mammalians -- 5.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 6 High Carbohydrate Diet-Induced Metabolic Syndrome in the Overweight Body: Association between Organ Dysfunction and Insulin Resistance -- 6.1 Introduction -- 6.2 Carbohydrate-Rich Nutrition and MetS -- 6.3 MetS and Cardiovascular Dysfunction -- 6.4 Structural

Alterations and Molecular Mechanisms of Cardiovascular Dysfunction in MetS -- 6.5 Electrical Alterations in the Hearts of MetS Individuals -- 6.6 Cellular Abnormalities in Ca²⁺ Homeostasis and Insulin Action in Mammalian MetS -- 6.7 Conclusions and Prevention Approaches -- Acknowledgments -- Abbreviations.

References -- Chapter 7 Caloric Restriction in Obesity and Diabetic Heart Disease -- 7.1 Introduction -- 7.1.1 Cardiovascular Consequences of Diabetes -- 7.2 Metabolic and Molecular Consequences of Diabetes -- 7.2.1 Oxidative Stress -- 7.2.2 Enhanced Inflammatory Response -- 7.2.3 Enhanced Cardiac Fibrosis -- 7.3 Modern Medical Therapies: Implications for the 'Diabetic' Heart -- 7.3.1 Pharmacological Approach, Bariatric Surgery, Intra-gastric Balloon -- 7.4 Lifestyle Modification -- 7.4.1 Caloric Restriction (CR) -- 7.4.1.1 CR Intracellular Mode of Action -- 7.4.2 Sirtuins -- 7.4.3 PGC-1 α -- 7.5 Summary and Future Perspectives -- Abbreviations -- References --

Chapter 8 Personalized Nutrition in Children with Crohn Disease -- 8.1 Introduction -- 8.2 Crohn Disease: An Inflammatory Bowel Disease -- 8.2.1 Crohn Disease and Ulcerative Colitis -- 8.2.2 Pathogenesis of IBD -- 8.2.3 Presentation and Epidemiology of IBD -- 8.2.4 Diagnosis of CD -- 8.3 Relevance of Nutrition and Dietary Factors in the Development of IBD -- 8.4 Nutritional Impacts of CD in Children -- 8.5 Nutritional Therapy for Children with Active CD -- 8.5.1 Induction of Remission with Exclusive Enteral Nutrition -- 8.6 General Aspects of Nutritional Management in Children with IBD -- 8.6.1 Overall Nutritional Care -- 8.6.2 Dietary Management of Functional Symptoms in Children with CD -- 8.7 Application of Current Understanding to the Development of Personalized Nutrition for Children with CD -- 8.7.1 Concepts to Guide Personalized Nutrition -- 8.7.2 Personalization of Nutritional Therapy to Induce Remission -- 8.7.3 Patient and Disease-Specific Factors to Guide Dietary Choices -- 8.7.4 Nutrigenomics, Nutrigenetics and Nutriepigenetics -- 8.8 Conclusions -- Abbreviations -- References --

Chapter 9 Personalized Nutrition in Chronic Kidney Disease: A New Challenge.

9.1 Chronic Kidney Disease: An Epidemic That Reflects Socio-Economic Differences -- 9.1.1 Kidney Diseases Are Not Rare: A Problem of Measure -- 9.1.2 The Main Markers of Kidney Function Are Also Basic Nutritional Markers -- 9.1.3 CKD Assessment: What Is Missed -- 9.1.4 The Epidemiology of Kidney Diseases Follows Wealth Distribution -- 9.2 Nutritional Approach to CKD: Ten Reasons Why One Size Does Not Fit All -- 9.2.1 Kidney Diseases Are Different -- 9.2.2 CKD Phases Are Different -- 9.2.3 Comorbidity Is Different -- 9.2.4 Cultures Are Different -- 9.2.5 Dietary Habits Are Different -- 9.2.6 Availability of Nutritional Support Is Different -- 9.2.7 Nephrologists (and Dietitians) Are Different -- 9.2.8 Life Phases Are Different -- 9.2.9 Patients Are Different -- 9.2.10 Most of the Previous Points May Change -- 9.3 Nutritional Issues in Different Phases of CKD -- 9.3.1 Early CKD Phases: Nephron Sparing -- 9.3.2 Late CKD Phases: Retarding Dialysis Start -- 9.3.3 Dialysis: Preserving Nutritional Status -- 9.3.4 Kidney Transplantation: Preserving Nutritional Status and Slowing CKD Progression -- 9.4 Some Suggestions on Specific Nutritional Issues in Different Diseases -- 9.4.1 Nephrotic Syndrome and the Case of Focal Segmental Glomerulosclerosis -- 9.4.2 Obesity-Related Kidney Disease and Diabetic Nephropathy -- 9.4.3 Autosomal Dominant Polycystic Kidney Disease (ADPKD) -- 9.4.4 Interstitial Disorders and Kidney Stones -- 9.4.5 Kidney Donation -- 9.5 Nutritional Issues in Particular CKD Populations -- 9.5.1 Pregnant Women with CKD -- 9.5.2 Children with CKD -- 9.6 What This Review Did Not Discuss: Suggestions for Further Research -- 9.7 Concluding Remarks --

Abbreviations -- References -- Chapter 10 Personalized Nutrition in
Hypercholesterolemia -- 10.1 Personalized Nutrition in
Hypercholesterolemia -- 10.2 Cardiovascular Diseases (CVD).
10.3 Coronary Heart Disease (CHD).
